Collaboration, License, Development and Commercialization Agreement By and Between Aratana Therapeutics, Inc. and Eli Lilly and Company acting on behalf of its Elanco Animal Health Division Effective as ofCollaboration, License, Development and Commercialization Agreement • August 5th, 2016 • Aratana Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledAugust 5th, 2016 Company IndustryThis Collaboration, License, Development and Commercialization Agreement , effective as of 22 April 2016 (the “Effective Date”), is entered into by and between Aratana Therapeutics, Inc., a Delaware corporation and having its office at 11400 Tomahawk Creek Parkway, Suite 340, Leawood, KS 66211 (“Licensor”) and Eli Lilly and Company, an Indiana corporation, operating on behalf of its Elanco Animal Health division and having its office at 2500 Innovation Way, Greenfield, Indiana 46140 and its Affiliates (“Elanco”).
AMENDMENT TO COLLABORATION, LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCollaboration, License, Development and Commercialization Agreement • August 4th, 2017 • Aratana Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledAugust 4th, 2017 Company IndustryThis Amendment to the Collaboration, License, Development and Commercialization Agreement (this “Amendment”), effective as of April 28, 2017, (the “Effective Date”) is entered into by and between Aratana Therapeutics, Inc., a Delaware corporation and having its office at 11400 Tomahawk Creek Parkway, Suite 340, Leawood, KS 66211 (“Aratana”) and Eli Lilly and Company, an Indiana corporation, operating on behalf of its Elanco Animal Health division and having its office at 2500 Innovation Way, Greenfield, Indiana 46140 and its Affiliates (“Elanco”).